Exploring the prognostic value of T follicular helper cell levels in chronic lymphocytic leukemia.
Chronic lymphocytic leukemia
Prognostic genes
Tfh
Time-to-first treatment
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 Sep 2024
28 Sep 2024
Historique:
received:
12
04
2024
accepted:
16
09
2024
medline:
29
9
2024
pubmed:
29
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) presents with heterogeneous clinical outcomes, suggesting varied underlying pathogenic mechanisms. This study aims to elucidate the impact of T follicular helper (Tfh) cells on CLL progression and prognosis. Gene expression profile data for CLL were collected from GSE22762 and GSE39671 datasets. Patients were divided into high and low groups using Tfh levels using the optimal cutoff value based on overall survival (OS) and time-to-first treatment (TTFT). Differential expression analysis was performed between these groups, followed by co-expression network analysis and single-sample Gene Set Enrichment Analysis (ssGSEA). Marker genes of Tfh cells were used to construct prognostic models. Additionally, 40 CLL patients were recruited and categorized based on median Tfh levels. Marker gene expression was assessed using RT-qPCR and Western Blot, and immune cell levels were determined through flow cytometry. The high group showed better prognosis compared to the low group. Among the 1121 differentially expressed genes identified, five co-expression networks were constructed, with the turquoise module showing the highest correlation with Tfh cells. Genes within this module significantly participate in cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, and natural killer cell mediated cytotoxicity. Tfh cells were significantly negatively correlated with activated B cells and positively correlated with Tregs. The Random Survival Forest (RSF) model identified 10 marker genes, and further analysis using Lasso regression and nomogram selected CLEC4A, RAE1, CD84, and PRDX1 as prognostic markers. In the high group, levels of CLEC4A and RAE1 were higher than in the low group, whereas CD84 and PRDX1 were lower. Flow cytometry revealed that the level of activated B cells in the high Tfh group was significantly lower than in the low Tfh group, while the level of Tregs is significantly higher in the high Tfh group. This study seeks to contribute to a more detailed understanding of the pathogenesis of CLL, delving into the prognostic significance of Tfh.
Identifiants
pubmed: 39341925
doi: 10.1038/s41598-024-73325-8
pii: 10.1038/s41598-024-73325-8
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22443Subventions
Organisme : the "Tianshan Innovation Team Plan" by the Science and Technology Department of Xinjiang Uygur Autonomous Region
ID : 2022D14008
Informations de copyright
© 2024. The Author(s).
Références
Kennedy, E. et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood 137 (22), 3064–3078 (2021).
doi: 10.1182/blood.2020005964
pubmed: 33512408
pmcid: 8176769
Kipps, T. J. et al. Chronic lymphocytic leukaemia. Nat. Rev. Dis. Primers 3, 16096 (2017).
doi: 10.1038/nrdp.2016.96
pubmed: 28102226
pmcid: 5336551
Hengeveld, P. J. et al. High-throughput proteomics identifies THEMIS2 as independent biomarker of treatment-free survival in untreated CLL. Hemasphere 7 (10), e951 (2023).
doi: 10.1097/HS9.0000000000000951
pubmed: 37731707
pmcid: 10508458
Agius, R. et al. Machine learning can identify newly diagnosed patients with CLL at high risk of infection. Nat. Commun. 11 (1), 363 (2020).
doi: 10.1038/s41467-019-14225-8
pubmed: 31953409
pmcid: 6969150
Wu, X. et al. Altered T follicular helper cell subsets and function in chronic lymphocytic leukemia. Front. Oncol. 11, 674492 (2021).
doi: 10.3389/fonc.2021.674492
pubmed: 33996605
pmcid: 8113764
Patel, P. S. et al. Translational regulation of TFH cell differentiation and autoimmune pathogenesis. Sci. Adv. 8 (25), eabo1782 (2022).
doi: 10.1126/sciadv.abo1782
pubmed: 35749506
pmcid: 9232117
Nie, Y., Yun, X., Zhang, Y. & Wang, X. Targeting metabolic reprogramming in chronic lymphocytic leukemia. Exp. Hematol. Oncol. 11 (1), 39 (2022).
doi: 10.1186/s40164-022-00292-z
pubmed: 35761419
pmcid: 9235173
Vaca, A. M. et al. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia 36 (5), 1324–1335 (2022).
doi: 10.1038/s41375-022-01519-y
pubmed: 35149845
Le Saos-Patrinos, C. et al. Elevated levels of circulatory follicular T helper cells in chronic lymphocytic leukemia contribute to B cell expansion. J. Leukoc. Biol. 113 (3), 305–314 (2023).
doi: 10.1093/jleuko/qiad006
pubmed: 36807447
Koh, C. H. et al. GITR agonism triggers antitumor immune responses through IL21-Expressing follicular helper T cells. Cancer Immunol. Res. 8 (5), 698–709 (2020).
doi: 10.1158/2326-6066.CIR-19-0748
pubmed: 32122993
Herold, T. et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 25 (10), 1639–1645 (2011).
doi: 10.1038/leu.2011.125
pubmed: 21625232
Chuang, H. Y. et al. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood 120 (13), 2639–2649 (2012).
doi: 10.1182/blood-2012-03-416461
pubmed: 22837534
pmcid: 3460686
Penter, L. et al. Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia Mirror Disease History. Cancer Discov. 11 (12), 3048–3063 (2021).
doi: 10.1158/2159-8290.CD-21-0276
pubmed: 34112698
pmcid: 8660953
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16 (5), 284–287 (2012).
doi: 10.1089/omi.2011.0118
pubmed: 22455463
pmcid: 3339379
Liu, Z. et al. Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat. Commun. 13 (1), 816 (2022).
doi: 10.1038/s41467-022-28421-6
pubmed: 35145098
pmcid: 8831564
Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell. Rep. 18 (1), 248–262 (2017).
doi: 10.1016/j.celrep.2016.12.019
pubmed: 28052254
Hallek, M. & Al-Sawaf, O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am. J. Hematol. 96 (12), 1679–1705 (2021).
doi: 10.1002/ajh.26367
pubmed: 34625994
Liang, T. et al. Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia. Front. Immunol. 13, 985280 (2022).
doi: 10.3389/fimmu.2022.985280
pubmed: 36211334
pmcid: 9539190
Roessner, P. M. & Seiffert, M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease? Leukemia 34 (8), 2012–2024 (2020).
doi: 10.1038/s41375-020-0873-2
pubmed: 32457353
pmcid: 8318881
Gowda, A. et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 111 (9), 4723–4730 (2008).
doi: 10.1182/blood-2007-07-099531
pubmed: 18182577
pmcid: 2343602
Yano, M. et al. Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy. Blood Adv. 6 (20), 5641–5654 (2022).
doi: 10.1182/bloodadvances.2021005883
pubmed: 35486482
pmcid: 9582588
Ahearne, M. J. et al. Enhancement of CD154/IL4 proliferation by the T follicular helper (tfh) cytokine, IL21 and increased numbers of circulating cells resembling tfh cells in chronic lymphocytic leukaemia. Br. J. Haematol. 162 (3), 360–370 (2013).
doi: 10.1111/bjh.12401
pubmed: 23710828
Bhatt, S. et al. Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood 126 (13), 1555–1564 (2015).
doi: 10.1182/blood-2015-01-624585
pubmed: 26194763
pmcid: 4582332
Qian, F. et al. Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia. FASEB J. 36 (5), e22328 (2022).
doi: 10.1096/fj.202200251R
pubmed: 35471732
Guarente, V. & Sportoletti, P. Lessons, challenges and Future Therapeutic opportunities for PI3K Inhibition in CLL. Cancers (Basel) 13 (6) (2021).
Chen, S. S. et al. Duvelisib eliminates CLL B cells, impairs CLL-Supporting cells, and overcomes Ibrutinib Resistance in a Xenograft Model. Clin. Cancer Res. 29 (10), 1984–1995 (2023).
doi: 10.1158/1078-0432.CCR-22-2386
pubmed: 37071496
pmcid: 10192081
Barshidi, A. et al. The role of exhausted natural killer cells in the immunopathogenesis and treatment of leukemia. Cell. Commun. Signal. 22 (1), 59 (2024).
doi: 10.1186/s12964-023-01428-2
pubmed: 38254135
pmcid: 10802000
Rubino, V. et al. Adaptive and innate cytotoxic effectors in chronic lymphocytic leukaemia (CLL) subjects with stable disease. Int. J. Mol. Sci. 24 (11) (2023).
Fisher, J. G. et al. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia 37 (10), 2036–2049 (2023).
doi: 10.1038/s41375-023-01984-z
pubmed: 37528310
pmcid: 10539165
Ruiz-Lafuente, N. et al. The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NFkappaB inhibitor. PLoS ONE 9 (10), e109533 (2014).
doi: 10.1371/journal.pone.0109533
pubmed: 25280001
pmcid: 4184842
Chiffoleau, E. C-Type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. Front. Immunol. 9, 227 (2018).
doi: 10.3389/fimmu.2018.00227
pubmed: 29497419
pmcid: 5818397
Yu, J., Sun, H., Cao, W., Song, Y. & Jiang, Z. Research progress on dendritic cell vaccines in cancer immunotherapy. Exp. Hematol. Oncol. 11 (1), 3 (2022).
doi: 10.1186/s40164-022-00257-2
pubmed: 35074008
pmcid: 8784280
Lemasson, Q., Akil, H., Feuillard, J. & Vincent-Fabert, C. Genetically Engineered Mouse models support a major role of Immune checkpoint-dependent immunosurveillance escape in B-Cell lymphomas. Front. Immunol. 12, 669964 (2021).
doi: 10.3389/fimmu.2021.669964
pubmed: 34113345
pmcid: 8186831
Wang, Z. H., Li, W., Dong, H. & Han, F. Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. Front. Oncol. 12, 1077436 (2022).
doi: 10.3389/fonc.2022.1077436
pubmed: 37078002
Lewinsky, H. et al. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia. J. Clin. Invest. 128 (12), 5465–5478 (2018).
doi: 10.1172/JCI96610
pubmed: 30277471
pmcid: 6264738
Klopotowska, M. et al. PRDX-1 supports the survival and antitumor activity of primary and CAR-Modified NK cells under oxidative stress. Cancer Immunol. Res. 10 (2), 228–244 (2022).
doi: 10.1158/2326-6066.CIR-20-1023
pubmed: 34853030